1Serganova I,Doubrovin M,Vider J,el al.Molecular imaging of tern-poral dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice[].Cancer Research.2004
2Dehdashti F,Mortimer JE,Siegel BA,et al.Positron tomographic as-sessment of estrogen receptors in breast cancer:comparison with FDG-PETand in vitro receptor assays[].The Journal of Nuclear Medicine.1995
3Fei X,Wang JQ,Miller KD,et al.Synthesis of[18F]Xeloda asnovel potential PET radiotracer for imaging enzymes in cancers[].Nuclear Medicine and Biology.2004
4Propper DJ,de Bono J,Saleem A,et al.Use of positron emissiontomography in pharmacokmetic studies to investigate therapeutic ad-vantage in a phase I study of120-hour intravenous infusion XR5000[].Journal of Clinical Oncology.2003
5Beer AJ,Haubner R,Sarbia M,et al.Positron emission tomographyusing[18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man[].Clinical Cancer Research.2006
6Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epi-dermal growth factorreceptor underlying responsiveness of non-small-cell lung cancer to gefitinib[].The New England Journal of Medicine.2004
7Saleem A,Brown GD,Brady F,et al.Metabolic activation of temo-zolomide measured in vroo using positron emission tomography[].Cancer Research.2003
8Kurdziel KA,Kiesewetter DO,Carson RE,et al.Biodistribution,Radiation Dose Estimates,and In Vivo Pgp Modulation Studies of18F-Paclitaxel in Nonhuman Primates[].Journal of Nuclear Med-icine.2003
9Waldherr Christian,et al.Monitoring antiproliferative responses to ki-nase inhibitor therapy in mice with 3’-deoxy-3’-18F-fluorothymi-dine PET[].J Nucl MedJ Nucl Med.2005
10Samen E,Thorell JO,Fredriksson A,et al.The tyrosine kinase in-hibitor PD153035:implication of labeling position on radiometabolitesformed in vitro[].Nuclear Medicine and Biology.2006
